newsfilter
← Latest News
ACCESS Newswire·

Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4

• Dosing is expected to begin by April, 2022 KELOWNA, BC / ACCESSWIRE / December 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to report that Ind